Life Sciences – Specialized Lending

Troutman Sanders has significant experience representing banks and lenders, venture debt funds and other non-banking lenders in transactions to provide financing to companies that specialize in biotechnology, medical devices, digital health, pharmaceuticals, healthcare services and other life sciences sectors. The borrowers we serve range from early stage and emerging growth to late stage public companies. Our clients will often structure these credit facilities to include mezzanine financings, warrants to purchase stock or rights to invest in subsequent equity rounds, or will require the borrower’s intellectual property to be used as collateral. While our finance attorneys are well-versed in the numerous issues that are typical for these life sciences transactions, including regulatory compliance and complex intellectual property issues, they also work closely with firm attorneys across other practices who specialize in these areas, including clinical trials and governmental investigation, to provide a comprehensive approach to each transaction.

  • Represented a secured lender in a $7.5 million growth capital term loan to a biopharmaceutical company.
  • Represented a medical technology company in obtaining a $50 million senior secured revolving credit facility.
  • Represented a lender in a $10 million “club” deal with a bio-medical company.
  • Represented a lender in a secured senior revolving line of credit to an advanced visualization medical device manufacturer in the amount of $7.5 million with a $15 million subordinate secured facility.
  • Represented a European lender in a €2 million senior secured debt financing to a venture-backed life sciences company.